

# National Board of Examinations

<b>Question Paper Name :</b>	DrNB Neurology Paper3
<b>Subject Name :</b>	DrNB Neurology Paper3
<b>Duration :</b>	180
<b>Total Marks :</b>	100
<b>Display Marks:</b>	No

**Maximum Instruction Time :** 0

**Question Number : 1 Question Id : 32718741034 Consider As Subjective : Yes**

- a) Basal ganglia circuitry underlying dystonia. [3]
- b) 2-axis classification of dystonia. [4]
- c) Treatment strategies of generalized dystonia. [3]

**Question Number : 2 Question Id : 32718741035 Consider As Subjective : Yes**

- a) Neurological manifestations of IgG4 related disorders. [3]
- b) Differential diagnosis of IgG4 related disorders. [4]
- c) Acute and long term treatment of neurological manifestations of IgG4 related disorders. [3]

**Question Number : 3 Question Id : 32718741036 Consider As Subjective : Yes**

Duchenne Muscular Dystrophy (DMD):

- a) Molecular genetics. [3]
- b) Clinical course and systemic involvement. [4]
- c) Recent advances in gene-based therapies. [3]

**Question Number : 4 Question Id : 32718741037 Consider As Subjective : Yes**

Metachromatic Leukodystrophy (MLD):

- a) Biochemical basis. [3]

- b) Clinical and MRI features. [4]
- c) Current and experimental treatment modalities. [3]

**Question Number : 5 Question Id : 32718741038 Consider As Subjective : Yes**

Describe Orthostatic Hypotension (OH) under the following heads:

- a) Diagnostic criteria of OH. [2]
- b) Causes of OH. [4]
- c) Pharmacological and non-pharmacological management of OH. [4]

**Question Number : 6 Question Id : 32718741039 Consider As Subjective : Yes**

Neurorehabilitation:

- a) Principles of neuroplasticity underlying neurorehabilitation. [3]
- b) Evidence-based rehabilitation strategies after ischemic stroke. [4]
- c) Role of artificial intelligence in neurorehabilitation. [3]

**Question Number : 7 Question Id : 32718741040 Consider As Subjective : Yes**

Describe the recent advances in multiple sclerosis under the following heads:

- a) 2024 updates in diagnostic criteria for MS. [4]
- b) Highly effective vs escalation therapy in relapsing remitting multiple sclerosis. [3]
- c) Current role of bruton tyrosine kinase inhibitors in management of multiple sclerosis. [3]

**Question Number : 8 Question Id : 32718741041 Consider As Subjective : Yes**

Anti-glial fibrillary acidic protein (GFAP) antibody associated autoimmunity:

- a) Immunopathogenesis. [3]
- b) Clinical spectrum and MRI findings. [4]
- c) Treatment strategies and prognosis [3]

**Question Number : 9 Question Id : 32718741042 Consider As Subjective : Yes**

Stem cell therapy in neurological diseases:

- a) Types of stem cells and their rationale for use in neurological disorders. [3]
- b) Current evidence in spinal cord injury and MS. [4]
- c) Ethical and regulatory challenges. [3]

**Question Number : 10 Question Id : 32718741043 Consider As Subjective : Yes**

Stiff person syndrome:

a) Immunopathogenesis. [3]

b) Diagnostic criteria. [3]

c) Treatment options and recent advances. [4]